Assessment of epidermal growth factor receptor with 99mTc-ethylenedicysteine-C225 monoclonal antibody

Anti-Cancer Drugs

Volumn 14, Issue 1, 2003, Pages 49-56

  Schechter, Naomi R ^a   Yang, David J ^a   Azhdarinia, Ali ^a   Kohanim, Sahar ^a   Wendtlll, Richard ^a   Oh, Chang Sok ^a   Hu, Mickey ^a   Yu, Dong Fang ^a   Bryant, Jerry ^a   Ang, K Kian ^a   Forster, Kenneth M ^a   Kim, E Edmund ^a   Podoloff, Donald A ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

99mTc EC C225; Antiangiogenesis; Epidermal growth factor receptor imaging

Indexed keywords

CETUXIMAB; CHELATING AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; ETHYLENEDICYSTEINE TC 99M; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOPSY; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CANCER RADIOTHERAPY; CELL DIVISION; CELL SURFACE; CONTROLLED STUDY; CYTOTOXICITY; DRUG DISTRIBUTION; DRUG TARGETING; FEMALE; GENE EXPRESSION; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; METASTASIS; MOUSE; NONHUMAN; NUDE MOUSE; PATIENT SELECTION; PRIORITY JOURNAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TISSUE DISTRIBUTION; WESTERN BLOTTING;

ANIMALS; ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; CELL LINE; CYSTEINE; FEMALE; HUMANS; MICE; MICE, NUDE; RATS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TECHNETIUM; TISSUE DISTRIBUTION;

EID: 0037268613     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200301000-00007     Document Type: Article

References (32)

1. Waxman ES, Herbst RS. The role of the epidermal growth factor receptor in the treatment of colorectal carcinoma. Semin Oncol Nurs 2002; 18:20-29.
2. Jung YD, Mansfield PF, Akagi M, Takeda A, Liu W, Bucana CD, et al. Effects of combination anti-vascular endothelial growth factor receptor and anti-epidermal growth factor receptor therapies on the growth of gastric cancer in a nude mouse model. Eur J Cancer 2002; 38:1133-1140.
3. Ciardiello F, Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 2001; 7:2958-2970.
4. Karashima T, Sweeney P, Slaton JW, Kim SJ, Kedar D, Izawa JI, et al. Inhibition of angiogenesis by the antiepidermal growth factor receptor antibody ImClone C225 in androgen-independent prostate cancer growing orthotopically in nude mice. Clin Cancer Res 2002; 8:1253-1264.
5. Kim ES, Khuri FR, Herbst RS. Epidermal growth factor receptor biology (IMC-C225). Curr Opin Oncol 2001; 13:506-513.
6. Prewett MC, Hooper AT, Bassi R, Ellis LM, Waksal HW, Hicklin DJ. Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts. Clin Cancer Res 2002; 8:994-1003.
7. Herbst RS, Langer CJ. Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers. Semin Oncol 2002; 29:27-36.
8. Burke PA, DeNardo SJ, Miers LA, Kukis DL, DeNardo GL. Combined modality radioimmunotherapy. Promise and peril. Cancer 2002; 94:1320-1331.
9. Harari PM, Huang SM. Radiation response modification following molecular inhibition of epidermal growth factor receptor signaling. Semin Radiat Oncol 2001; 11:281-289.
10. Nasu S, Ang KK, Fan Z, Milas L. C225 antiepidermal growth factor receptor antibody enhances tumor radiocurability. Int J Radiat Oncol Biol Phys 2001; 51:474-477.
11. 2 core. Inorg Chem 1981; 20:1629-1632.
12. Verbruggen AM, Nosco DL, Van Nerom CG, Bormans GM, Adriaens PJ, De Roo MJ. Tc-99m-L,L-ethylenedicysteine: a renal imaging agent. I. Labelling and evaluation in animals. J Nucl Med 1992; 33:551-557.
13. Van Nerom CG, Bormans GM, De Roo MJ, Verbruggen AM. First experience in healthy volunteers with Tc-99m-L,L-ethylenedicysteine, a new renal imaging agent. Eur J Nucl Med 1993; 20:738-746.
14. Surma MJ, Wiewiora J, Liniecki J. Usefulness of Tc-99m-N,N′-ethylene-1-dicysteine complex for dynamic kidney investigations. Nucl Med Commun 1994; 15:628-635.
15. 99mTc-Ethylenedicysteine-folate: a new tumor imaging agent. Synthesis, labeling and evaluation in animals. Cancer Biother Radiopharm 1998; 13:427-435.
16. 99mTc-ethylenedicysteine-colchicine for evaluation of antiangiogenic effects. Anti-Cancer Drugs 1999; 10:685-692.
17. 99mTc-labeled metronidazole. Pharm Res 1999; 16:743-750.
18. 99mTc-EC-Annexin V. Cancer Biother Radiopharm 2001; 16:73-84.
19. 99mTc-EC-endostatin. Cancer Biother Radiopharm 2002; 17:233-246.
20. Bonner JA, De Los Santos J, Waksal HW, Needle MN, Trummel HQ, Raisch KP. Epidermal growth factor receptor as a therapeutic target in head and neck cancer. Semin Radiat Oncol 2002; 12;11-20.
21. Bancroft CC, Chen Z, Yeh J, Sunwoo JB, Yeh NT, Jackson S, et al. Effects of pharmacologic antagonists of epidermal growth factor receptor, PI3 K and MEK signal kinases on NF-kappaB and AP-1 activation and IL-8 and VEGF expression in human head and neck squamous cell carcinoma lines. Int J Cancer 2002; 99:538-548.
22. Herbst RS, Kim ES, Harari PM. IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody, for treatment of head and neck cancer. Expert Opin Biol Ther 2001; 1:719-732.
23. Ratner S, Clarke HT. The action of formaldehyde upon cysteine. J Am Chem Soc 1937; 59:200-206.
24. Blondeau P, Berse C, Gravel D. Dimerization of an intermediate during the sodium in liquid ammonia reduction of L-thiazolidine-4-carboxylic acid. Can J Chem 1967; 45:49-52.
25. Sion-Vardy N, Fliss DM, Prinsloo I, Shoham-Vardi I, Benharroch D. Neoangiogenesis in squamous cell carcinoma of the larynx - biological and prognostic associations. Pathol Res Pract 2001; 197:1-5.
26. Guang-Wu H, Sunagawa M, Jie-En L, Shimada S, Gang Z, Tokeshi Y, et al. The relationship between microvessel density, the expression of vascular endothelial growth factor (VEGF), and the extension of nasopharyngeal carcinoma. Laryngoscope 2000; 110:2066-2069.
27. Xiangming C, Hokita S, Natsugoe S, Tanabe G, Baba M, Takao S, et al. Angiogenesis as an unfavorable factor related to lymph node metastasis in early gastric cancer. Ann Surg Oncol 1998; 5:585-589.
28. Ugurel S, Rappl G, Tilgen W, Reinhold U. Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival. J Clin Oncol 2001; 19:577-583.
29. Feltis BA, Sahar DA, Kim AS, Saltzman DA, Leonard AS, Sielaff TD. Cyclooxygenase-2 inhibition augments the hepatic antitumor effect of oral Salmonella typhimurium in a model of mouse metastatic colon cancer. Dis Colon Rectum 2002; 45:1023-1028.
30. Decatris M, Santhanam S, O'Byrne K. Potential of interferon-alpha in solid tumours: part 1. BioDrugs 2002; 16:261-281.
31. Baselga J, Albanell J. Targeting epidermal growth factor receptor in lung cancer. Curr Oncol Rep 2002; 4:317-324.
32. Herbst RS, Shin DM. Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. Cancer 2002; 94:1593-1611.